CDK13 inhibitor

DRUG CLASS:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	osimertinib + AU-16770 Sensitive: D – Preclinical osimertinib + AU-16770 Sensitive : D	osimertinib + AU-16770 Sensitive: D – Preclinical osimertinib + AU-16770 Sensitive : D
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	osimertinib + AU-15506 Sensitive: D – Preclinical osimertinib + AU-15506 Sensitive : D	osimertinib + AU-15506 Sensitive: D – Preclinical osimertinib + AU-15506 Sensitive : D

Associations(2)